Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirabegron - Astellas Pharma

Next Previous
Drug Profile

Mirabegron - Astellas Pharma

Alternative Names: Betanis; Betmiga; Betmiga PR; Myrbetriq; Myrbetriq Granules; YM-178

Latest Information Update: 18 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Class Acetamides; Antihyperglycaemics; Erectile dysfunction therapies; Ethanolamines; Small molecules; Thiazoles; Urologics
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • Phase III Interstitial cystitis
  • Phase I/II Erectile dysfunction
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 10 Feb 2026 Astellas Pharma reaches a settlement with Lupin to resolve the ongoing US patent dispute involving Myrbetriq® (mirabegron)
  • 10 Nov 2025 Launched for Overactive bladder in Norway (PO)
  • 15 Oct 2025 Launched for Overactive bladder in Spain (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top